A COVID-19 vaccine developed by Sanofi and GlaxoSmithKline showed a robust immune response in early-stage clinical trial results, enabling them to move to a late-stage study, the companies announced on Monday.
source https://www.cbc.ca/news/health/sanofi-glaxosmithkline-set-to-start-phase-3-trials-for-covid-19-vaccine-after-earlier-setback-1.6029502?cmp=rss
No comments:
Post a Comment